Sai Life Sciences shares rally 9% after Q2 results; net profit rises 17%, revenue up 23%
The stock also touched a fresh 52-week high of Rs 1,750 during the trading session.
Sai Life Sciences Ltd., one of India’s fastest-growing Contract Research, Development and Manufacturing Organisations (CRDMOs), reported a net profit of Rs 98 crore for the September 2026 quarter, compared with Rs 84 crore in the corresponding quarter last year.
Revenue from operations increased to Rs 659 crore in Q2FY27 from Rs 537 crore in Q2FY26, registering a growth of 23% YoY.
EBITDA rose 20% to Rs 187 crore from Rs 156 crore in the year-ago quarter. However, the company’s PAT margin moderated to 15% from 16% in the corresponding period last year.
Sai Life Sciences: H1FY27 performance
For the first half of FY27, Sai Life Sciences reported healthy growth across its key financial parameters.Revenue from operations increased 17% to Rs 1,213 crore in H1FY27 from Rs 1,034 crore in H1FY26. EBITDA grew 19% to Rs 335 crore from Rs 281 crore, while profit after tax (PAT) rose 19% to Rs 172 crore compared with Rs 144 crore in the year-ago period.
The company incurred capital expenditure (capex) of Rs 621 crore during the first half of FY27.
Commenting on the performance, Krishna Kanumuri, Managing Director and CEO of Sai Life Sciences, said Q2FY27 was a strong quarter for the company, supported by sustained business momentum and progress across key strategic priorities.
He highlighted increasing traction with global pharmaceutical companies, wider adoption of the company’s integrated outsourcing model and continued investments in capacity and capabilities.
Also Read |Dhanteras 2026: Buying gold today? Here’s how to choose between jewellery, coins, ETFs and SGBs
He also noted that customer engagements were increasingly expanding from individual projects into larger strategic relationships spanning discovery, development and manufacturing.
Sai Life Sciences share price performance
Sai Life Sciences shares have gained around 89% over the past year, reflecting the stock’s strong performance during the period. The company currently commands a market capitalisation of approximately Rs 33,966 crore.
On the valuation front, the stock trades at a price-to-earnings (P/E) ratio of 90.79, a price-to-sales ratio of 9.37 and a price-to-book value ratio of 13.22.
Disclaimer: The views/recommendations mentioned in this article, wherever applicable, are those of the respective SEBI-registered Research Analyst/brokerage and have been reproduced/reported with due attribution. They should not be construed as the views or recommendations of The Economic Times Digital or the journalist. Readers are advised to consider the original research report and make their investment decisions based on their own assessment. Brokerage disclaimers here
